Organization (Industry)
Mallinckrodt (Ireland)
ClinicalTrials.gov lists Mallinckrodt (Ireland) as lead sponsor of 87 trials. It has 18 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Mallinckrodt (Ireland): 87 lead-sponsored trials and 4 legal-entity registrations.
Disease areas (132)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 28 |
| Multiple Sclerosis | 11 |
| Postoperative Pain | 11 |
| Hypertension, Pulmonary | 10 |
| Arthritis, Rheumatoid | 8 |
Showing 5 of 132 disease areas.
Trials by start year as sponsor or collaborator (28)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 6 |
| 2020 | 1 |
| 2019 | 9 |
| 2018 | 12 |
| 2017 | 14 |
Showing 10 of 28 years.
Recruitment duration, a model prediction: none of the 87 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (18)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| IV Acetaminophen | 10 |
| ACTHAR Gel (ACTH) | 8 |
| Oral Acetaminophen | 3 |
| Repository Corticotropin Injection | 3 |
| MORPHINE | 2 |
Showing 5 of 18 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=14) | 54% on time (n=13) |
Journals published in (188)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Pediatrics | 13 |
| The New England journal of medicine | 8 |
| Ophthalmology | 7 |
| The Journal of pediatrics | 7 |
| The Journal of thoracic and cardiovascular surgery | 7 |
Showing 5 of 188 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 716 | 1 | 2021-10-12 |
FDA recalls (8)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| INOmax DSIR -(delivery system) delivers INOMAX (nitric oxide for inhalation) therapy gas into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, Model Number: 10007 | Class II | 2022-06-23 |
| Amitiza (lubiprostone) capsules, 8 mcg, 60-count bottle, Rx only, Manufactured by: Sucampo Pharma Americas, LLC, NDC 64764-080-60 | Class II | 2019-05-13 |
| Amitiza (lubiprostone) capsules, 24 mcg, 60-count bottle, Rx only, Manufactured by: Sucampo Pharma Americas, LLC, NDC 64764-240-60 | Class II | 2019-05-13 |
| MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04 | Class II | 2015-05-15 |
| Thallous Chloride Tl 201 Injection, Diagnostic Sterile, Non-Pyrogenic Solution, a) 2.8 mL (NDC 0019N12028) b) 6.3ml (NDC 0019N12063) For Intravenous Administration, each milliliter contains 37 MBq (1 mCi) Thallous Chloride Tl 201 (no carrier added) at date and time of calibration, 9 mg sodium chloride and 0.9% (v/v) benzyl alcohol as a preservative, RX, Mallinckrodt Inc., St. Louis, MO 63134 | Class III | 2012-07-30 |
Showing 5 of 8 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2002-01-02 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Curium US LLC | Maryland Heights, US | FDA, Health Canada | |
| Mallinckrodt Inc. | St. Louis, US | Health Canada |
Organization relationships (57)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| The Cleveland Clinic | Co sponsors trial with | 3 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 2 |
| University of Colorado System | Co sponsors trial with | 2 |
| University of California System | Co sponsors trial with | 1 |
| Canadian Institutes of Health Research | Co sponsors trial with | 1 |
Showing 5 of 57 relationships.
Latest dated events (918)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-05-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-01-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2022-11-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 918 events.
Biomarker capability evidence (230)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial collaborator | Named in trial inclusion criteria |
| AGT | Trial collaborator | Named in trial inclusion criteria |
| AGT | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 230 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.